Defining the risks of mesenchymal stromal cell therapy. 2010

Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
Texas A&M Health Science College of Medicine, Institute for Regenerative Medicine at Scott & White, Temple, TX 76502, USA. Prockop@medicine.tamhsc.edu

Abstract We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

UI MeSH Term Description Entries
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016922 Cellular Senescence Process by which cells irreversibly stop dividing and enter a state of permanent growth arrest without undergoing CELL DEATH. Senescence can be induced by DNA DAMAGE or other cellular stresses, such as OXIDATIVE STRESS. Aging, Cell,Cell Aging,Cell Senescence,Replicative Senescence,Senescence, Cellular,Senescence, Replicative,Cell Ageing,Cellular Ageing,Cellular Aging,Ageing, Cell,Ageing, Cellular,Aging, Cellular,Senescence, Cell
D017154 Stromal Cells Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere. Cell, Stromal,Cells, Stromal,Stromal Cell
D045164 Mesenchymal Stem Cell Transplantation Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Stem Cell Transplantation, Mesenchymal,Transplantation, Mesenchymal Stem Cell
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
December 2016, Cytotherapy,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
February 2018, Critical care medicine,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
January 2018, Transplantation,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
January 2025, Cell transplantation,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
December 2018, Current opinion in organ transplantation,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
January 2014, Digestive diseases (Basel, Switzerland),
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
January 2017, Digestive diseases (Basel, Switzerland),
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
June 2018, Journal of hepatology,
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
June 2023, Bioengineering (Basel, Switzerland),
Darwin J Prockop, and Malcolm Brenner, and Willem E Fibbe, and Edwin Horwitz, and Katarina Le Blanc, and Donald G Phinney, and Paul J Simmons, and Luc Sensebe, and Armand Keating
January 2019, Journal of extracellular vesicles,
Copied contents to your clipboard!